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A two-year and seven-month-old boy presented to the Emergency Department at Sultan Qaboos University Hospital, 
Muscat, Oman, in 2019, with a two-day history of 
uprolling of eyeballs, unresponsiveness and drooling 
of saliva lasting for seconds. There was no abnormal 
limb movement or loss of tone.  The episodes were 
followed by a postictal state that lasted 30 minutes. 
There were no triggers for the episodes, such as fever 
or intercurrent illness. The patient was born at term 
gestation to a consanguineous marriage. Antenatal, 
birth and family history were unremarkable. His 
developmental milestones were appropriate for his age 
and his immunisation was up-to-date.  A sleep electro- 
encephalogram (EEG) showed abnormal interictal 
generalised epileptiform discharges with no associated 
clinical accompaniment. There were bilateral occipital 
epileptiform discharges with slowing over the left 




Figure 1: Sagittal T1-weighted magnetic resonance images (MRIs) of the brain of a two-year and seven-month-old boy 
before (A) and after (B) intravenous gadolinium contrast administration. They show a mass (asterisk) arising from the 
both above and below the floor of the third ventricle (red arrows). Accordingly, this mass has both vertical and horizontal 
planes of attachment to the floor of the third ventricle classifying it radiologically as Delalande type III. It occupies most 
of the suprasellar and interpeduncular cisterns. It compresses the optic chiasm (white arrows) and pituitary stalk (White 
arrowhead) anteriorly. Coronal (C) and axial (D) T2-weighted MRIs show the mass having a heterogenous hyperintense 
signal. It is seen stretching the optic tracts bilaterally (yellow arrows) in (D).
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posterior head region. In view of some lateralising 
features on EEG, MRI of the brain was done within 
three weeks of initial presentation, which revealed 
features of a hypothalamic hamartoma (HH; Figures 1 
and 2). Formal visual field assessment was not possible 
due to the patient’s young age. However, no visual 
symptoms were observed and endocrine workup was 
normal.  Initial seizure control was achieved with 
levetiracetam reaching a dose of 40 mg/kg/day. Two 
months later, he developed multiple, sudden onset, 
unprovoked and uncontrollable laughing episodes that 
were occurring for no obvious reasons, suggestive of 
gelastic seizures. Postictally, he was immediately back 
to his baseline with no tiredness or sleepiness. Repeated 
routine EEG did not capture the events and showed 
no clear epileptiform abnormality except bilateral 
posterior slowing with left temporal dominance. 
Long-term video EEG was not performed. The 
episodes of gelastic seizures were difficult to control 
and required the administration of topiramate (6 mg/
kg/day) as well as a short course of phenytoin (6 mg/
kg/day) to control a cluster of focal seizures. Currently, 
he is on two anti-epileptic medications (levetiracetam 
and topiramate). Eight months later during follow-up, 
the father of the child reported mild hyperactivity. 
There was no evidence of neuroregression. During the 
write-up of this article, the patient was awaiting formal 
assessment with the developmental and behavioural 
paediatric team.
Although he was not yet seizure-free, the 
episodes were reasonably controlled with 1–2 brief 
daily episodes of eyelid twitching and occasional 
gelastic seizures once in 1–2 weeks.  The parents were 
offered the option of surgical intervention, but decided 
against it.
Comment
As a rare developmental malformation, HH can 
display diverse clinical manifestations. It may present 
with intractable seizures, central precocious puberty 
and cognitive and neuropsychiatric disturbances. 
Seizures associated with HH can be of variable types 
and include focal seizures with impaired awareness, 
generalised tonic-clonic seizures, epileptic spasms, 
atonic, tonic, focal seizures with retained awareness 
and the hallmark gelastic seizures.1 Based on the 
radiological features, the HH of the current patient 
was classified as Delalande type III.2 The patient 
initially presented with focal seizure with impaired 
awareness and later developed gelastic seizures, which 
are a unique type of seizures that are usually seen in 
early childhood. Gelastic seizures are characterised 
by frequent brief attacks of inappropriate laughter.3 
The EEG during a gelastic seizure is usually normal 
or may show non-specific abnormalities, which may 
contribute to the difficulty in establishing the diagnosis 
when gelastic seizures are the sole presentation. The 
seizures in HH are thought to be due to either the 
intrinsic epileptogenicity of the hamartoma itself or 
contributed by the extensive epileptogenic networks 
and possible kindling-like relationship between the 
HH and the cortex.4,5 This epileptogenic spread could 
possibly explain the EEG findings in the current 
patient.
Most patients with epilepsy secondary to HH 
develop an associated mood disorder, behavioural 
issues and/or cognitive delay. A significant proportion 
of patients with HH and epilepsy may present 
with central precocious puberty. However, growth 
hormone deficiency, hypothyroidism and adrenal 
insufficiency are rare. Although diabetes insipidus is 
not seen in non-operated HH, it is frequently seen 
postoperatively.6
Treatment of HH-associated epilepsy is chall- 
enging and complete seizure freedom with anti-
seizure medications is rarely achieved. Behavioural 
and learning difficulties as well as cognitive delay lead 
to an overall developmental impairment contributing 
to the increased morbidity associated with HH. 
Treatment strategies in such cases of progressive 
encephalopathy associated with HH should be based 
on multidisciplinary care, including neurologists, 
 
Figure 2: Magnetic resonance imaging (MRI) of the 
brain of a two-year and seven-month-old boy showing a 
hypothalamic (tuber cinereum) hamartoma (asterisk). It 
shows (A & B) hyperintense signal on fluid-attenuated 
inversion recovery and T2 MRIs. Axial diffusion-
weighted MRI (C) and apparent diffusion coefficient 
map (D) images showing no evidence of diffusion 
restriction in this lesion.
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neuropsychologists and neurosurgeons. Therapeutic 
options include anti-seizure medications, ketogenic 
diet therapy and vagal nerve stimulation. Neurosurgical 
options include microsurgical resection, endoscopic 
disconnection, stereotactic laser ablation therapy, 
gamma knife surgery and laser interstitial thermal 
therapies.  Although surgical intervention remains 
the best treatment option for achieving seizure 
control in drug refractory cases, it is associated with 
a high risk of postoperative long-term endocrine 
dysfunction, especially with disconnection surgeries. 
Newer surgical techniques—including stereotactic 
radiofrequency thermo-coagulation, gamma knife 
surgery and laser interstitial thermal therapies—are 
reported to have better outcomes, though long-term 
follow-up of such patients is needed to monitor the 
neurodevelopmental and endocrine functions.7 
Therefore, multidisciplinary care with regular follow 
up and monitoring is recommended in such cases 
to make timely decisions based on individual case 
progress and evolution.8
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